PubRank

K A Jacobson

Author PubWeight™ 257.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001 9.90
2 Nomenclature and classification of purinoceptors. Pharmacol Rev 1994 5.32
3 Direct observation of brownian motion of lipids in a membrane. Proc Natl Acad Sci U S A 1991 3.91
4 Diffusion of injected macromolecules within the cytoplasm of living cells. Proc Natl Acad Sci U S A 1981 3.61
5 125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol 1994 2.65
6 Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. J Med Chem 1985 2.52
7 Structural mosaicism on the submicron scale in the plasma membrane. Biophys J 1998 2.50
8 The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol 2013 2.48
9 Unconfined lateral diffusion and an estimate of pericellular matrix viscosity revealed by measuring the mobility of gold-tagged lipids. J Cell Biol 1993 2.47
10 Adenosine A3 receptor stimulation and cerebral ischemia. Eur J Pharmacol 1994 2.33
11 Spatial Fourier analysis of video photobleaching measurements. Principles and optimization. Biophys J 1991 2.13
12 Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors. J Med Chem 1985 2.12
13 2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem 1994 2.10
14 Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci 1997 2.09
15 Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem 1995 1.92
16 A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol 1994 1.87
17 [3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. Proc Natl Acad Sci U S A 1986 1.85
18 Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem 2000 1.85
19 Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. J Med Chem 1993 1.84
20 Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. Br J Pharmacol 1998 1.80
21 Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. Br J Pharmacol 1994 1.77
22 Functionalized congeners of 1,3-dipropyl-8-phenylxanthine: potent antagonists for adenosine receptors that modulate membrane adenylate cyclase in pheochromocytoma cells, platelets and fat cells. Life Sci 1986 1.69
23 Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. Biochemistry 1999 1.64
24 A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. Mol Pharmacol 1997 1.63
25 A physiological role of the adenosine A3 receptor: sustained cardioprotection. Proc Natl Acad Sci U S A 1998 1.63
26 Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev 1992 1.62
27 Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. J Med Chem 1998 1.61
28 Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 1998 1.61
29 Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. J Clin Invest 1996 1.57
30 A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol 1992 1.57
31 A functionalized congener approach to adenosine receptor antagonists: amino acid conjugates of 1,3-dipropylxanthine. Mol Pharmacol 1986 1.55
32 Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol 1996 1.54
33 The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. J Biol Chem 1999 1.54
34 Probing the adenosine receptor with adenosine and xanthine biotin conjugates. FEBS Lett 1985 1.52
35 Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem 1997 1.51
36 Direct measurement of lateral transport in membranes by using time-resolved spatial photometry. Proc Natl Acad Sci U S A 1985 1.51
37 Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A 1989 1.50
38 Molecular probes for extracellular adenosine receptors. Biochem Pharmacol 1987 1.47
39 Apparent affinity of some 8-phenyl-substituted xanthines at adenosine receptors in guinea-pig aorta and atria. Br J Pharmacol 1987 1.45
40 Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem 2000 1.44
41 Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Mol Pharmacol 1991 1.42
42 A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. Mol Pharmacol 1987 1.42
43 Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett 1986 1.42
44 G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Mol Pharmacol 1995 1.40
45 Induction of cortical oscillations in spreading cells by depolymerization of microtubules. Cell Motil Cytoskeleton 2001 1.35
46 Modelling the P2Y purinoceptor using rhodopsin as template. Drug Des Discov 1995 1.35
47 Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Mol Pharmacol 1996 1.33
48 Cloning, expression, and characterization of the unique bovine A1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis. J Biol Chem 1992 1.32
49 Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking. J Med Chem 2001 1.32
50 The A2 adenosine receptor: guanine nucleotide modulation of agonist binding is enhanced by proteolysis. Mol Pharmacol 1991 1.32
51 Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem 1998 1.32
52 Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J Pharmacol Exp Ther 1991 1.31
53 Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. J Med Chem 1998 1.31
54 Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem 1996 1.31
55 Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus. J Neurosci 1997 1.29
56 Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5'-monophosphate. Br J Pharmacol 1996 1.27
57 A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged simulated ischemia. Am J Physiol 1997 1.27
58 Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications. Bioorg Med Chem Lett 2001 1.26
59 Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J Med Chem 1995 1.26
60 [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. Biochem Pharmacol 2001 1.25
61 Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists. J Med Chem 1999 1.25
62 Molecular modeling of adenosine receptors. I. The ligand binding site on the A1 receptor. Drug Des Discov 1992 1.25
63 Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. Biochem Biophys Res Commun 1996 1.23
64 Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des Discov 1999 1.21
65 Conjugates of catecholamines. 1. N-alkyl-functionalized carboxylic acid congeners and amides related to isoproterenol. J Med Chem 1983 1.20
66 A mouse model for vitiligo. J Invest Dermatol 1986 1.19
67 Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol 2001 1.18
68 Studies on the mechanism of polyethylene glycol-mediated cell fusion using fluorescent membrane and cytoplasmic probes. J Cell Biol 1983 1.18
69 Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding. Biochem Pharmacol 1992 1.17
70 High affinity acylating antagonists for the A1 adenosine receptor: identification of binding subunit. Mol Pharmacol 1988 1.17
71 A [3H]amine congener of 1,3-dipropyl-8-phenylxanthine. A new radioligand for A2 adenosine receptors of human platelets. FEBS Lett 1986 1.16
72 Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors. J Biol Chem 1994 1.16
73 Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood 1996 1.14
74 Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem 1996 1.13
75 125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. Mol Pharmacol 1995 1.13
76 Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D. FASEB J 2000 1.12
77 Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem 2001 1.12
78 Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes. Mol Cell Biochem 2001 1.11
79 Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur J Pharmacol 1994 1.11
80 Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Eur J Pharmacol 1996 1.11
81 Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation. Biochem Pharmacol 2000 1.11
82 The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. Biochem Biophys Res Commun 1997 1.10
83 Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists. J Med Chem 1997 1.09
84 Reply to: 'the discovery of a new class of synaptic transmitters in smooth muscle fifty years ago and amelioration of coronary artery thrombosis'. Acta Physiol (Oxf) 2013 1.09
85 Demonstration of distinct agonist and antagonist conformations of the A1 adenosine receptor. J Biol Chem 1989 1.09
86 Characterization of the locomotor depression produced by an A2-selective adenosine agonist. FEBS Lett 1990 1.08
87 Effects of chronic administration of adenosine A1 receptor agonist and antagonist on spatial learning and memory. Eur J Pharmacol 1993 1.08
88 Acyclic analogues of deoxyadenosine 3',5'-bisphosphates as P2Y(1) receptor antagonists. J Med Chem 2000 1.08
89 Conjugates of catecholamines. II. In vitro and in vivo pharmacological activity of N-alkyl-functionalized carboxylic acid congeners and amides related to isoproterenol. Mol Pharmacol 1983 1.08
90 Demonstration of both A1 and A2 adenosine receptors in DDT1 MF-2 smooth muscle cells. Mol Pharmacol 1990 1.07
91 Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem 1999 1.07
92 6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem 1996 1.06
93 The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. Bioorg Med Chem Lett 2000 1.06
94 Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives. J Med Chem 1994 1.05
95 Cardiac myocytes rendered ischemia resistant by expressing the human adenosine A1 or A3 receptor. FASEB J 1998 1.04
96 A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci U S A 1992 1.03
97 18F-labeled insulin: a prosthetic group methodology for incorporation of a positron emitter into peptides and proteins. Biochemistry 1989 1.03
98 Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist. Exp Cell Res 1998 1.03
99 Activation of the A3 adenosine receptor affects cell cycle progression and cell growth. Naunyn Schmiedebergs Arch Pharmacol 2000 1.02
100 Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain. Cell Mol Neurobiol 1993 1.02
101 Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. Eur J Pharmacol 1995 1.02
102 N6-functionalized congeners of adenosine with high potency at A2-adenosine receptors: potential ligands for affinity chromatography. Biochem Biophys Res Commun 1986 1.02
103 Some novel approaches to the design and synthesis of peptide-catecholamine conjugates. Biopolymers 1983 1.02
104 Induction of apoptosis in rat cardiocytes by A3 adenosine receptor activation and its suppression by isoproterenol. Exp Cell Res 2000 1.00
105 CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol 2011 0.99
106 Chronic adenosine A1 receptor agonist and antagonist: effect on receptor density and N-methyl-D-aspartate induced seizures in mice. Eur J Pharmacol 1994 0.99
107 The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol 2008 0.99
108 Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists. J Med Chem 1998 0.99
109 Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A2A receptor. Eur J Pharmacol 1994 0.99
110 Measurements of the diffusion of macromolecules injected into the cytoplasm of living cells. Cold Spring Harb Symp Quant Biol 1982 0.98
111 Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur J Pharmacol 1996 0.98
112 Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. J Med Chem 1996 0.98
113 Purification and characterization of bovine cerebral cortex A1 adenosine receptor. Arch Biochem Biophys 1990 0.98
114 Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX). J Biol Chem 1998 0.97
115 Multiple components of the A1 adenosine receptor-adenylate cyclase system are regulated in rat cerebral cortex by chronic caffeine ingestion. J Clin Invest 1988 0.97
116 Trifunctional agents as a design strategy for tailoring ligand properties: irreversible inhibitors of A1 adenosine receptors. Bioconjug Chem 1991 0.97
117 Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2Y-purinoceptors. Br J Pharmacol 1995 0.97
118 Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors. Endocrinology 2000 0.96
119 Adenosine receptor prodrugs: synthesis and biological activity of derivatives of potent, A1-selective agonists. J Pharm Sci 1994 0.96
120 Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochem Biophys Res Commun 1997 0.96
121 Synthesis using ring closure metathesis and effect on nucleoside transport of a (N)-methanocarba S-(4-nitrobenzyl)thioinosine derivative. Org Lett 2001 0.96
122 Characterization of human striatal A2-adenosine receptors using radioligand binding and photoaffinity labeling. J Recept Res 1992 0.96
123 Comparative studies on the affinities of ATP derivatives for P2x-purinoceptors in rat urinary bladder. Br J Pharmacol 1994 0.95
124 Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1993 0.94
125 Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur J Pharmacol 1999 0.94
126 Evidence that a novel 8-phenyl-substituted xanthine derivative is a cardioselective adenosine receptor antagonist in vivo. J Cardiovasc Pharmacol 1987 0.94
127 Analysis of agonist-antagonist interactions at A1 adenosine receptors. Mol Pharmacol 1990 0.93
128 Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol Biochem Behav 1993 0.93
129 The effects of adenosine A3 receptor stimulation on seizures in mice. Eur J Pharmacol 1995 0.93
130 Angiotensin II-induced apoptosis in rat cardiomyocyte culture: a possible role of AT1 and AT2 receptors. J Hypertens 2001 0.93
131 Glycoprotein nature of the A2-adenosine receptor binding subunit. Mol Pharmacol 1990 0.93
132 (N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets. J Thromb Haemost 2006 0.92
133 Further characterization of the renovascular effects of N6-cyclohexyladenosine in the isolated perfused rat kidney. J Pharmacol Exp Ther 1987 0.92
134 Adenosine: a prototherapeutic concept in neurodegeneration. Ann N Y Acad Sci 1995 0.92
135 Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists. J Med Chem 1999 0.92
136 A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. Biochemistry 1995 0.92
137 How adhesion, migration, and cytoplasmic calcium transients influence interleukin-1beta mRNA stabilization in human monocytes. Cell Motil Cytoskeleton 2004 0.92
138 Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist. Eur J Pharmacol 1996 0.92
139 Effects of N6-cyclopentyl adenosine and 8-cyclopentyl-1,3-dipropylxanthine on N-methyl-D-aspartate induced seizures in mice. Eur J Pharmacol 1993 0.92
140 Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int 1998 0.91
141 A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation. Mol Pharmacol 2002 0.91
142 Conjugates of catecholamines. IV. In vitro and in vivo pharmacological activity of monodisperse oligopeptide conjugates. J Pharmacol Exp Ther 1983 0.91
143 Conjugates of catecholamines. III. Synthesis and characterization of monodisperse oligopeptides conjugates related to isoproterenol. Int J Pept Protein Res 1983 0.91
144 Characterization of adenosine receptors in intact cultured heart cells. Biochem Pharmacol 1994 0.90
145 Non-xanthine heterocycles: activity as antagonists of A1- and A2-adenosine receptors. Biochem Pharmacol 1988 0.90
146 Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem 1996 0.90
147 Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist. Eur J Pharmacol 1999 0.89
148 Identification of an adenosine receptor domain specifically involved in binding of 5'-substituted adenosine agonists. J Biol Chem 1994 0.89
149 Affinity chromatography of the bovine cerebral cortex A1 adenosine receptor. FEBS Lett 1989 0.89
150 Xanthine functionalized congeners as potent ligands at A2-adenosine receptors. J Med Chem 1987 0.89
151 The effects of urine on the viability and activity of lymphocytes. J Urol 1976 0.89
152 Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann N Y Acad Sci 1997 0.88
153 8-cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry 1997 0.88
154 Comparative molecular field analysis of selective A3 adenosine receptor agonists. Bioorg Med Chem 1995 0.87
155 A1- and A2-selective adenosine antagonists: in vivo characterization of cardiovascular effects. J Pharmacol Exp Ther 1987 0.86
156 Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors. J Med Chem 1994 0.86
157 Adenosine receptor prodrugs: towards kidney-selective dialkylxanthines. J Pharmacol Exp Ther 1989 0.86
158 Visual methods for the nanomolar detection of electrophilic reagents. J Biochem Biophys Methods 1983 0.86
159 Presence of both A1 and A2a adenosine receptors in human cells and their interaction. Biochem Biophys Res Commun 1995 0.86
160 XAC, a functionalized congener of 1,3-dialkylxanthine, antagonizes A1 adenosine receptor-mediated inhibition of renin secretion in vitro. Arch Int Pharmacodyn Ther 1987 0.86
161 A selective agonist affinity label for A3 adenosine receptors. Biochem Biophys Res Commun 1994 0.86
162 Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis. Biochem Biophys Res Commun 2001 0.85
163 A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists. Nucleosides Nucleotides 1998 0.85
164 Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res 1987 0.85
165 Roles of BCL-2 and caspase 3 in the adenosine A3 receptor-induced apoptosis. J Mol Neurosci 2001 0.85
166 [(3)H]XAC (xanthine amine congener) is a radioligand for A(2)-adenosine receptors in rabbit striatum. Neurochem Int 1991 0.85
167 Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett 1998 0.85
168 Molecular probes for muscarinic receptors: derivatives of the M1-antagonist telenzepine. Bioconjug Chem 1992 0.85
169 Functionalized congener approach to muscarinic antagonists: analogues of pirenzepine. J Med Chem 1991 0.85
170 Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model. J Med Chem 1998 0.84
171 Molecular modeling studies of human A3 adenosine antagonists: structural homology and receptor docking. J Chem Inf Comput Sci 1999 0.84
172 Site-directed mutagenesis of the human adenosine A2A receptor. Critical involvement of Glu13 in agonist recognition. Eur J Pharmacol 1996 0.84
173 Interaction of dihydropyridine calcium channel agonists and antagonists with adenosine receptors. Pharmacol Toxicol 1987 0.84
174 Structure-activity relationships for G2 checkpoint inhibition by caffeine analogs. Int J Oncol 2000 0.84
175 Stimulation of Xenopus P2Y1 receptor activates CFTR in A6 cells. Pflugers Arch 2004 0.83
176 Functionalized congener approach for the design of novel muscarinic agents. Synthesis and pharmacological evaluation of N-methyl-N-[4-(1-pyrrolidinyl)-2-butynyl] amides. J Med Chem 1990 0.82
177 Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine. J Pharmacol Exp Ther 1995 0.82
178 High affinity acylating antagonists for muscarinic receptors. Life Sci 1992 0.82
179 Solution and interfacial properties of gramicidin pertinent to its effect on membranes. Biochim Biophys Acta 1972 0.82
180 Effects of chronic caffeine on adenosine, dopamine and acetylcholine systems in mice. Arch Int Pharmacodyn Ther 1995 0.82
181 Desensitization of the canine A2a adenosine receptor: delineation of multiple processes. Mol Pharmacol 1994 0.82
182 Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors. J Med Chem 1987 0.82
183 Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors. Bioconjug Chem 1999 0.82
184 Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors. J Med Chem 1996 0.81
185 Autoradiographic localization of mouse brain adenosine receptors with an antagonist ([3H]xanthine amine congener) ligand probe. Neurosci Lett 1988 0.81
186 Solubilized rabbit striatal A2a-adenosine receptors: stability and antagonist binding. Arch Biochem Biophys 1993 0.81
187 CPX, a selective A1-adenosine-receptor antagonist, regulates intracellular pH in cystic fibrosis cells. Am J Physiol 1995 0.81
188 Chronic NMDA receptor stimulation: therapeutic implications of its effect on adenosine A1 receptors. Eur J Pharmacol 1995 0.81
189 Modulation of apoptosis by adenosine in the central nervous system: a possible role for the A3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders. Ann N Y Acad Sci 1997 0.80
190 Extracellular adenine nucleotides regulate Na+/H+ exchanger NHE3 activity in A6-NHE3 transfectants by a cAMP/PKA-dependent mechanism. J Membr Biol 2002 0.80
191 Polarization of adenosine effects on intracellular pH in A6 renal epithelial cells. Mol Pharmacol 1997 0.80
192 Effect of adenosine on Na+ and Cl- currents in A6 monolayers. Receptor localization and messenger involvement. J Membr Biol 1996 0.80
193 Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies. J Med Chem 2001 0.80
194 Persistent activation by and receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1 MF-2 cells and in guinea pig heart. Mol Pharmacol 1997 0.80
195 Synthesis and purine receptor affinity of 6-oxopurine nucleosides and nucleotides containing (N)-methanocarba-pseudoribose rings. Bioorg Med Chem Lett 2001 0.80
196 Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists. J Med Chem 1996 0.80
197 Apparent heterogeneity of cardiac A1 adenosine receptors as revealed by radioligand binding experiments on N-ethylmaleimide-treated membranes. Naunyn Schmiedebergs Arch Pharmacol 1991 0.80
198 Potent convulsant actions of the adenosine receptor antagonist, xanthine amine congener (XAC). Life Sci 1989 0.80
199 Probing adenosine receptors using biotinylated purine derivatives. Methods Enzymol 1990 0.79
200 Characterization of "mini-nucleotides" as P2X receptor agonists in rat cardiomyocyte cultures. An integrated synthetic, biochemical, and theoretical study. J Med Chem 1999 0.79
201 Activation of A(3) adenosine receptor induces calcium entry and chloride secretion in A(6) cells. J Membr Biol 2000 0.79
202 Additive effects of late preconditioning produced by monophosphoryl lipid A and the early preconditioning mediated by adenosine receptors and KATP channel. Circulation 1999 0.79
203 Liquid chromatographic assay for cerebrospinal fluid serotonin. Life Sci 1986 0.79
204 Differential effects of flavonoids on testosterone-metabolizing cytochrome P450s. Life Sci 1997 0.79
205 The A3 adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via a specific action on Rho proteins. Ann N Y Acad Sci 2001 0.79
206 Improvement of cold tolerance by selective A1 adenosine receptor antagonists in rats. Pharmacol Biochem Behav 1990 0.78
207 Selective A(3) adenosine receptor antagonists: water-soluble 3, 5-diacyl-1,2,4-trialkylpyridinium salts and their oxidative generation from dihydropyridine precursors. J Med Chem 1999 0.77
208 Adenosine and ischemic preconditioning. Curr Pharm Des 1999 0.77
209 Muscarinic receptor binding and activation of second messengers by substituted N-methyl-N-[4-(1-azacycloalkyl)-2-butynyl]acetamides. J Med Chem 1991 0.77
210 Synthesis and adenosine receptor affinity of 7-beta-D-ribofuranosylxanthine. Nucleosides Nucleotides 1998 0.77
211 Autoradiographic localization of adenosine A1 receptors in rat brain using [3H]XCC, a functionalized congener of 1,3-dipropylxanthine. Neurosci Lett 1987 0.76
212 Immunological identification of A2 adenosine receptors by two antipeptide antibody preparations. Mol Pharmacol 1992 0.76
213 Pharmacogenomics of cystic fibrosis. Mol Interv 2001 0.75
214 An adenosine A3 receptor-selective agonist does not modulate calcium-activated potassium currents in hippocampal CA1 pyramidal neurons. Prog Brain Res 1999 0.75
215 In vivo imaging of insulin receptors in monkeys using 18F-labeled insulin and positron emission tomography. Diabetes 1992 0.75
216 Summary: symposium on optical methods applicable to renal research. Kidney Int 1991 0.75
217 Regulation of A1 adenosine receptors by amiodarone and electrical stimulation in rat myocardial cells in vitro. Biochem Pharmacol 1997 0.75
218 Effects of theophylline and dibutyryl-cAMP on adenosine receptors and heart rate in cultured cardiocytes. J Basic Clin Physiol Pharmacol 1996 0.75
219 Liquid chromatographic assay for cerebrospinal fluid normetanephrine. Life Sci 1987 0.75
220 New high-performance liquid chromatographic procedure for the detection and quantification of beta-phenylethylamine. J Chromatogr 1987 0.75
221 In vitro and in vivo betamimetic activity of congeners of isoproterenol. Proc West Pharmacol Soc 1982 0.75
222 Betamimetic activity of peptide catecholamine conjugates. Proc West Pharmacol Soc 1983 0.75
223 Effects of protein nutrition on lymphocyte transformation. Surg Forum 1977 0.75
224 Uptake of glucose analogs reflects the rate of contraction of cultured myocytes. J Basic Clin Physiol Pharmacol 1999 0.75
225 Simultaneous determination of histamine and N tau-methylhistamine with high-performance liquid chromatography using electrochemical detection. Anal Biochem 1986 0.75
226 Syphilis control in Texas: a correlate. Int J Dermatol 1973 0.75
227 An irreversible A1-selective adenosine agonist preconditions rabbit heart. Can J Cardiol 1996 0.75
228 Identification of cell-mediated immunity blocking factors in human urine. Surg Forum 1977 0.75
229 Electrochemical detection of biogenic amines following acylation by N-hydroxysuccinimide esters. FEBS Lett 1985 0.75
230 Regulation of adenosine receptors in cultured heart cells. Adv Exp Med Biol 1995 0.75